2017
DOI: 10.1186/s12906-016-1525-y
|View full text |Cite
|
Sign up to set email alerts
|

The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor

Abstract: BackgroundMonoamine oxidase-B (MAO-B) inhibitors are widely used in the treatment of Parkinson’s disease. They increase vital monoamine neurotransmitters in the brain. However, there is a need for safer natural reversible MAO inhibitors with MAO-B selectivity. Our previous studies showed that Psoralea corylifolia seeds (PCS) extract contains compounds that inhibit monoamine oxidase-B.MethodsIn this study, six of PCS constituents sharing a benzopyrone structure were investigated. The compounds Biochanin-A (BIO-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
20
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 41 publications
(21 citation statements)
references
References 48 publications
1
20
0
Order By: Relevance
“…3 , 4 , and 5 inhibited AChE in a competitive but partially mixed manner, whereas 3 and 5 inhibited MAO-B in a competitive manner. The majority of AChE inhibitors described to date are mixed or partially mixed inhibitors 22 , 26 , 57 , whereas the MAO-B inhibitors described are usually competitive type 58 60 .…”
Section: Discussionmentioning
confidence: 99%
“…3 , 4 , and 5 inhibited AChE in a competitive but partially mixed manner, whereas 3 and 5 inhibited MAO-B in a competitive manner. The majority of AChE inhibitors described to date are mixed or partially mixed inhibitors 22 , 26 , 57 , whereas the MAO-B inhibitors described are usually competitive type 58 60 .…”
Section: Discussionmentioning
confidence: 99%
“…BCA also exerts a neuroprotective effect against L-glutamate-induced cytotoxicity, which plays a crucial role in neuronal cell death in various neurodegenerative diseases and reduces glutathione levels (Tan et al, 2013; Biradar et al, 2014). BCA is a potent, reversible, and selective oxidase-B (MAO-B) inhibitor because of the hydrophobic interactions between BCA and MAO-B, and MAO-B inhibitors are widely used in the treatment of PD and have potential in the future treatment of AD (Zarmouh et al, 2017). BCA effectively inhibits the activity of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) not only via a mitochondria-dependent apoptosis pathway but also by binding the allosteric site of BACE1; BACE1 accumulation is among the major histological hallmarks of AD (Youn et al, 2016).…”
Section: Neuroprotective Effects Of Bcamentioning
confidence: 99%
“…Interestingly, the role of reported plant sourced natural compounds with promising antioxidant and anti-inflammatory activities that prevent or delay the occurrence and progression of NDDs, has been pursuing the interest of many researchers in the quest for additional candidates with better potentials [ 16 18 ]. Having said that, Glucomoringin-isothiocyanate (GMG-ITC) was reported to have wide range of biological activities such as anti-inflammatory, anti-oxidant, antimicrobial and antiulcer [ 19 22 ].…”
Section: Introductionmentioning
confidence: 99%